Caspase 3 Explained

Caspase-3 is a caspase protein that interacts with caspase-8 and caspase-9. It is encoded by the CASP3 gene. CASP3 orthologs[1] have been identified in numerous mammals for which complete genome data are available. Unique orthologs are also present in birds, lizards, lissamphibians, and teleosts.

The CASP3 protein is a member of the cysteine-aspartic acid protease (caspase) family.[2] Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes that undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. This protein cleaves and activates caspases 6 and 7; and the protein itself is processed and activated by caspases 8, 9, and 10. It is the predominant caspase involved in the cleavage of amyloid-beta 4A precursor protein, which is associated with neuronal death in Alzheimer's disease.[3] Alternative splicing of this gene results in two transcript variants that encode the same protein.[4]

Caspase-3 shares many of the typical characteristics common to all currently-known caspases. For example, its active site contains a cysteine residue (Cys-163) and histidine residue (His-121) that stabilize the peptide bond cleavage of a protein sequence to the carboxy-terminal side of an aspartic acid when it is part of a particular 4-amino acid sequence.[5] [6] This specificity allows caspases to be incredibly selective, with a 20,000-fold preference for aspartic acid over glutamic acid.[7] A key feature of caspases in the cell is that they are present as zymogens, termed procaspases, which are inactive until a biochemical change causes their activation. Each procaspase has an N-terminal large subunit of about 20 kDa followed by a smaller subunit of about 10 kDa, called p20 and p10, respectively.[8]

Substrate specificity

Under normal circumstances, caspases recognize tetra-peptide sequences on their substrates and hydrolyze peptide bonds after aspartic acid residues. Caspase 3 and caspase 7 share similar substrate specificity by recognizing tetra-peptide motif Asp-x-x-Asp.[9] The C-terminal Asp is absolutely required while variations at other three positions can be tolerated.[10] Caspase substrate specificity has been widely used in caspase based inhibitor and drug design.[11]

Structure

Caspase-3, in particular, (also known as CPP32/Yama/apopain)[12] [13] [14] is formed from a 32 kDa zymogen that is cleaved into 17 kDa and 12 kDa subunits. When the procaspase is cleaved at a particular residue, the active heterotetramer can then be formed by hydrophobic interactions, causing four anti-parallel beta-sheets from p17 and two from p12 to come together to make a heterodimer, which in turn interacts with another heterodimer to form the full 12-stranded beta-sheet structure surrounded by alpha-helices that is unique to caspases.[8] [15] When the heterodimers align head-to-tail with each other, an active site is positioned at each end of the molecule formed by residues from both participating subunits, though the necessary Cys-163 and His-121 residues are found on the p17 (larger) subunit.[15]

Mechanism

The catalytic site of caspase-3 involves the thiol group of Cys-163 and the imidazole ring of His-121. His-121 stabilizes the carbonyl group of the key aspartate residue, while Cys-163 attacks to ultimately cleave the peptide bond. Cys-163 and Gly-238 also function to stabilize the tetrahedral transition state of the substrate-enzyme complex through hydrogen bonding.[15] In vitro, caspase-3 has been found to prefer the peptide sequence DEVDG (Asp-Glu-Val-Asp-Gly) with cleavage occurring on the carboxy side of the second aspartic acid residue (between D and G).[15] [16] Caspase-3 is active over a broad pH range that is slightly higher (more basic) than many of the other executioner caspases. This broad range indicates that caspase-3 will be fully active under normal and apoptotic cell conditions.[17]

Activation

Caspase-3 is activated in the apoptotic cell both by extrinsic (death ligand) and intrinsic (mitochondrial) pathways.[8] [18] The zymogen feature of caspase-3 is necessary because if unregulated, caspase activity would kill cells indiscriminately.[19] As an executioner caspase, the caspase-3 zymogen has virtually no activity until it is cleaved by an initiator caspase after apoptotic signaling events have occurred.[20] One such signaling event is the introduction of granzyme B, which can activate initiator caspases, into cells targeted for apoptosis by killer T cells.[21] [22] This extrinsic activation then triggers the hallmark caspase cascade characteristic of the apoptotic pathway, in which caspase-3 plays a dominant role.[6] In intrinsic activation, cytochrome c from the mitochondria works in combination with caspase-9, apoptosis-activating factor 1 (Apaf-1), and ATP to process procaspase-3.[23] These molecules are sufficient to activate caspase-3 in vitro, but other regulatory proteins are necessary in vivo.Mangosteen (Garcinia mangostana) extract has been shown to inhibit the activation of caspase 3 in B-amyloid treated human neuronal cells.[24]

Inhibition

One means of caspase inhibition is through the IAP (inhibitor of apoptosis) protein family, which includes c-IAP1, c-IAP2, XIAP, and ML-IAP.[15] XIAP binds and inhibits initiator caspase-9, which is directly involved in the activation of executioner caspase-3.[23] During the caspase cascade, however, caspase-3 functions to inhibit XIAP activity by cleaving caspase-9 at a specific site, preventing XIAP from being able to bind to inhibit caspase-9 activity.[25]

Interactions

Caspase 3 has been shown to interact with:

Biological function

Caspase-3 has been found to be necessary for normal brain development as well as its typical role in apoptosis, where it is responsible for chromatin condensation and DNA fragmentation.[16] Elevated levels of a fragment of Caspase-3, p17, in the bloodstream is a sign of a recent myocardial infarction.[47] It is now being shown that caspase-3 may play a role in embryonic and hematopoietic stem cell differentiation.[48]

See also

Further reading

External links

Notes and References

  1. Web site: OrthoMaM phylogenetic marker: CASP3 coding sequence . 2009-12-20 . https://web.archive.org/web/20160303190753/http://www.orthomam.univ-montp2.fr/orthomam/data/cds/detailMarkers/ENSG00000164305_CASP3.xml . 2016-03-03 . dead .
  2. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J . Human ICE/CED-3 protease nomenclature . Cell . 87 . 2 . 171 . October 1996 . 8861900 . 10.1016/S0092-8674(00)81334-3 . 5345060 . free .
  3. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, Nicholson DW . Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation . Cell . 97 . 3 . 395–406 . April 1999 . 10319819 . 10.1016/s0092-8674(00)80748-5. 17524567 . free .
  4. Web site: Entrez Gene: CASP3 caspase 3, apoptosis-related cysteine peptidase.
  5. Wyllie AH . Apoptosis: an overview . British Medical Bulletin . 53 . 3 . 451–65 . 1997 . 9374030 . 10.1093/oxfordjournals.bmb.a011623. free .
  6. Perry DK, Smyth MJ, Stennicke HR, Salvesen GS, Duriez P, Poirier GG, Hannun YA . Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis . The Journal of Biological Chemistry . 272 . 30 . 18530–3 . July 1997 . 9228015 . 10.1074/jbc.272.30.18530 . free .
  7. Stennicke HR, Renatus M, Meldal M, Salvesen GS . Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8 . The Biochemical Journal . 350 . 2 . 563–8 . September 2000 . 10947972 . 1221285 . 10.1042/0264-6021:3500563 .
  8. Salvesen GS . Caspases: opening the boxes and interpreting the arrows . Cell Death and Differentiation . 9 . 1 . 3–5 . January 2002 . 11803369 . 10.1038/sj.cdd.4400963 . 31274387 .
  9. Agniswamy J, Fang B, Weber IT . Plasticity of S2-S4 specificity pockets of executioner caspase-7 revealed by structural and kinetic analysis . The FEBS Journal . 274 . 18 . 4752–65 . September 2007 . 17697120 . 10.1111/j.1742-4658.2007.05994.x . 1860924 .
  10. Fang B, Boross PI, Tozser J, Weber IT . Structural and kinetic analysis of caspase-3 reveals role for s5 binding site in substrate recognition . Journal of Molecular Biology . 360 . 3 . 654–66 . July 2006 . 16781734 . 10.1016/j.jmb.2006.05.041 .
  11. Weber IT, Fang B, Agniswamy J . Caspases: structure-guided design of drugs to control cell death . Mini Reviews in Medicinal Chemistry . 8 . 11 . 1154–62 . October 2008 . 18855730 . 10.2174/138955708785909899 .
  12. Fernandes-Alnemri T, Litwack G, Alnemri ES . CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme . The Journal of Biological Chemistry . 269 . 49 . 30761–4 . December 1994 . 10.1016/S0021-9258(18)47344-9 . 7983002 . free .
  13. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM . Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase . Cell . 81 . 5 . 801–9 . June 1995 . 7774019 . 10.1016/0092-8674(95)90541-3 . 18866447 . free .
  14. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA . Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis . Nature . 376 . 6535 . 37–43 . July 1995 . 7596430 . 10.1038/376037a0 . 1995Natur.376...37N . 4240789 .
  15. Lavrik IN, Golks A, Krammer PH . Caspases: pharmacological manipulation of cell death . The Journal of Clinical Investigation . 115 . 10 . 2665–72 . October 2005 . 16200200 . 1236692 . 10.1172/JCI26252 .
  16. Porter AG, Jänicke RU . Emerging roles of caspase-3 in apoptosis . Cell Death and Differentiation . 6 . 2 . 99–104 . February 1999 . 10200555 . 10.1038/sj.cdd.4400476 . free .
  17. Stennicke HR, Salvesen GS . Biochemical characteristics of caspases-3, -6, -7, and -8 . The Journal of Biological Chemistry . 272 . 41 . 25719–23 . October 1997 . 9325297 . 10.1074/jbc.272.41.25719 . free .
  18. Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ, Los M . Apoptosis and cancer: mutations within caspase genes . Journal of Medical Genetics . 46 . 8 . 497–510 . August 2009 . 19505876 . 10.1136/jmg.2009.066944 . free .
  19. Boatright KM, Salvesen GS . Mechanisms of caspase activation . Current Opinion in Cell Biology . 15 . 6 . 725–31 . December 2003 . 14644197 . 10.1016/j.ceb.2003.10.009 .
  20. Walters J, Pop C, Scott FL, Drag M, Swartz P, Mattos C, Salvesen GS, Clark AC . A constitutively active and uninhibitable caspase-3 zymogen efficiently induces apoptosis . The Biochemical Journal . 424 . 3 . 335–45 . December 2009 . 19788411 . 2805924 . 10.1042/BJ20090825 .
  21. Gallaher BW, Hille R, Raile K, Kiess W . Apoptosis: live or die--hard work either way! . Hormone and Metabolic Research . 33 . 9 . 511–9 . September 2001 . 11561209 . 10.1055/s-2001-17213 . 36623826 .
  22. Katunuma N, Matsui A, Le QT, Utsumi K, Salvesen G, Ohashi A . Novel procaspase-3 activating cascade mediated by lysoapoptases and its biological significances in apoptosis . Advances in Enzyme Regulation . 41 . 1 . 237–50 . 2001 . 11384748 . 10.1016/S0065-2571(00)00018-2 .
  23. Li P, Nijhawan D, Wang X . Mitochondrial activation of apoptosis . Cell . 116 . 2 Suppl . S57–9, 2 p following S59 . January 2004 . 15055583 . 10.1016/S0092-8674(04)00031-5 . 5180966 . free .
  24. Moongkarndi P, Srisawat C, Saetun P, Jantaravinid J, Peerapittayamongkol C, Soi-ampornkul R, Junnu S, Sinchaikul S, Chen ST, Charoensilp P, Thongboonkerd V, Neungton N . Protective effect of mangosteen extract against beta-amyloid-induced cytotoxicity, oxidative stress and altered proteome in SK-N-SH cells . Journal of Proteome Research . 9 . 5 . 2076–86 . May 2010 . 20232907 . 10.1021/pr100049v .
  25. Denault JB, Eckelman BP, Shin H, Pop C, Salvesen GS . Caspase 3 attenuates XIAP (X-linked inhibitor of apoptosis protein)-mediated inhibition of caspase 9 . The Biochemical Journal . 405 . 1 . 11–9 . July 2007 . 17437405 . 1925235 . 10.1042/BJ20070288 .
  26. Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES . Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria . The Journal of Biological Chemistry . 277 . 16 . 13430–7 . April 2002 . 11832478 . 10.1074/jbc.M108029200 . free .
  27. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Litwack G, Alnemri ES . Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases . Proceedings of the National Academy of Sciences of the United States of America . 93 . 25 . 14486–91 . December 1996 . 8962078 . 26159 . 10.1073/pnas.93.25.14486 . 1996PNAS...9314486S . free .
  28. Selvakumar . P. . Sharma . RK. . Role of calpain and caspase system in the regulation of N-myristoyltransferase in human colon cancer (Review). . Int J Mol Med . 19 . 5 . 823–7 . May 2007 . 10.3892/ijmm.19.5.823. 17390089 . free .
  29. Shu HB, Halpin DR, Goeddel DV . Casper is a FADD- and caspase-related inducer of apoptosis . Immunity . 6 . 6 . 751–63 . June 1997 . 9208847 . 10.1016/S1074-7613(00)80450-1 . free .
  30. Han DK, Chaudhary PM, Wright ME, Friedman C, Trask BJ, Riedel RT, Baskin DG, Schwartz SM, Hood L . MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclXL and initiates cell death . Proceedings of the National Academy of Sciences of the United States of America . 94 . 21 . 11333–8 . October 1997 . 9326610 . 23459 . 10.1073/pnas.94.21.11333 . 1997PNAS...9411333H . free .
  31. Forcet C, Ye X, Granger L, Corset V, Shin H, Bredesen DE, Mehlen P . The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation . Proceedings of the National Academy of Sciences of the United States of America . 98 . 6 . 3416–21 . March 2001 . 11248093 . 30668 . 10.1073/pnas.051378298 . 2001PNAS...98.3416F . free .
  32. Samali A, Cai J, Zhivotovsky B, Jones DP, Orrenius S . Presence of a pre-apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of jurkat cells . The EMBO Journal . 18 . 8 . 2040–8 . April 1999 . 10205158 . 1171288 . 10.1093/emboj/18.8.2040 .
  33. Xanthoudakis S, Roy S, Rasper D, Hennessey T, Aubin Y, Cassady R, Tawa P, Ruel R, Rosen A, Nicholson DW . Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis . The EMBO Journal . 18 . 8 . 2049–56 . April 1999 . 10205159 . 1171289 . 10.1093/emboj/18.8.2049 .
  34. Ruzzene M, Penzo D, Pinna LA . Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells . The Biochemical Journal . 364 . Pt 1 . 41–7 . May 2002 . 11988074 . 1222543 . 10.1042/bj3640041.
  35. Chen YR, Kori R, John B, Tan TH . Caspase-mediated cleavage of actin-binding and SH3-domain-containing proteins cortactin, HS1, and HIP-55 during apoptosis . Biochemical and Biophysical Research Communications . 288 . 4 . 981–9 . November 2001 . 11689006 . 10.1006/bbrc.2001.5862 .
  36. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC . IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs . Cancer Research . 58 . 23 . 5315–20 . December 1998 . 9850056 .
  37. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH . An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7 . Biochemistry . 40 . 4 . 1117–23 . January 2001 . 11170436 . 10.1021/bi001603q .
  38. Lee ZH, Lee SE, Kwack K, Yeo W, Lee TH, Bae SS, Suh PG, Kim HH . Caspase-mediated cleavage of TRAF3 in FasL-stimulated Jurkat-T cells . Journal of Leukocyte Biology . 69 . 3 . 490–6 . March 2001 . 10.1189/jlb.69.3.490 . 11261798 . 34256107 .
  39. Leo E, Deveraux QL, Buchholtz C, Welsh K, Matsuzawa S, Stennicke HR, Salvesen GS, Reed JC . TRAF1 is a substrate of caspases activated during tumor necrosis factor receptor-alpha-induced apoptosis . The Journal of Biological Chemistry . 276 . 11 . 8087–93 . March 2001 . 11098060 . 10.1074/jbc.M009450200 . free .
  40. Suzuki Y, Nakabayashi Y, Takahashi R . Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death . Proceedings of the National Academy of Sciences of the United States of America . 98 . 15 . 8662–7 . July 2001 . 11447297 . 37492 . 10.1073/pnas.161506698 . 2001PNAS...98.8662S . free .
  41. Silke J, Hawkins CJ, Ekert PG, Chew J, Day CL, Pakusch M, Verhagen AM, Vaux DL . The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites . The Journal of Cell Biology . 157 . 1 . 115–24 . April 2002 . 11927604 . 2173256 . 10.1083/jcb.200108085 .
  42. Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW, Liddington RC, Salvesen GS . Structural basis for the inhibition of caspase-3 by XIAP . Cell . 104 . 5 . 791–800 . March 2001 . 11257232 . 10.1016/S0092-8674(01)00274-4 . 17915093 . free .
  43. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC . The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases . The EMBO Journal . 16 . 23 . 6914–25 . December 1997 . 9384571 . 1170295 . 10.1093/emboj/16.23.6914 .
  44. Deveraux QL, Takahashi R, Salvesen GS, Reed JC . X-linked IAP is a direct inhibitor of cell-death proteases . Nature . 388 . 6639 . 300–4 . July 1997 . 9230442 . 10.1038/40901 . 1997Natur.388..300D . 4395885 . free .
  45. Suzuki Y, Nakabayashi Y, Nakata K, Reed JC, Takahashi R . X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes . The Journal of Biological Chemistry . 276 . 29 . 27058–63 . July 2001 . 11359776 . 10.1074/jbc.M102415200 . free.
  46. Ohtsubo T, Kamada S, Mikami T, Murakami H, Tsujimoto Y . Identification of NRF2, a member of the NF-E2 family of transcription factors, as a substrate for caspase-3(-like) proteases . Cell Death and Differentiation . 6 . 9 . 865–72 . September 1999 . 10510468 . 10.1038/sj.cdd.4400566 . free .
  47. Agosto M, Azrin M, Singh K, Jaffe AS, Liang BT . Serum caspase-3 p17 fragment is elevated in patients with ST-segment elevation myocardial infarction: a novel observation . Journal of the American College of Cardiology . 57 . 2 . 220–1 . January 2011 . 21211695 . 10.1016/j.jacc.2010.08.628 . free .
  48. Abdul-Ghani M, Megeney LA . Rehabilitation of a contract killer: caspase-3 directs stem cell differentiation . Cell Stem Cell . 2 . 6 . 515–6 . June 2008 . 18522841 . 10.1016/j.stem.2008.05.013 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Caspase 3".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.